Core Insights - Verrica Pharmaceuticals reported a sequential quarterly growth of 32.8% in Q2 2025, with 13,434 YCANTH dispensed applicator units, indicating strong demand for the product [1][2] - The company received an $8 million milestone payment from Torii Pharmaceutical for the initiation of a global Phase 3 program for common warts [1][2] Company Performance - The growth in dispensed applicator units reflects the effectiveness of Verrica's focused commercial strategy, leading to increased prescriptions from dermatology and pediatric practices [2] - The company attributes its growth to a robust patient access strategy, strong reimbursement, and an extensive distribution network [2] Product Information - YCANTH (VP-102) is the first FDA-approved treatment for molluscum contagiosum, a contagious skin disease affecting approximately six million people in the U.S., primarily children [3][4] - The product is delivered via a single-use applicator, allowing for precise dosing and targeted administration [3] Financial Developments - The company has amended its Credit Agreement with OrbiMed and has a collaboration agreement with Torii Pharmaceutical, which includes potential additional milestone payments [2] - Approximately 225 million lives are eligible for YCANTH coverage, with commercially insured patients paying only $25 per treatment visit [3] Future Outlook - Verrica is looking forward to updates on its development strategy for VP-315, aimed at treating basal cell carcinoma [2][4]

– Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule – – Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of YCANTH® (TO-208 in Japan) for molluscum contagiosum in Japan; approval decision expected by the end of 2025 – – Torii to fund the first $40 million of out-of-pocket costs for the global study, representing approximately 90% of the current clinical budget – – Common warts affects approxim ...

Verrica Pharmaceuticals Inc (VRCA) 2025 Conference June 04, 2025 04:20 PM ET Speaker0 Good afternoon. Welcome to day one of the Jefferies Healthcare Conference. My name is Dennis Ng, biotech analyst here at Jefferies. I have the great pleasure of having Verica Pharmaceuticals here with us. We have CEO Jason Rieger. Welcome. So why don't we kick things off with just a brief background and overview about the company, where you are today, and just kind of what's been happening over the last few years, just sor ...

WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference in New York City. Jefferies Global Healthcare Conference, June 3-5, 2025 Event details: Date: Wednesday, J ...

Group 1 - Verrica Pharmaceuticals held its Q1 2025 Corporate Update Conference Call on May 13, 2025, with key participants including the CEO, CFO, and COO [1][3] - The call included discussions on the commercialization of YCANTH for treating molluscum contagiosum in the U.S., revenue growth, regulatory developments, and the company's product candidates [4][5] - Management emphasized the importance of forward-looking statements regarding the company's business strategy and operations, highlighting potential risks and uncertainties [4][5]

Core Insights - Verrica Pharmaceuticals reported $3.4 million in revenue from YCANTH, driven by a record dispensing of over 10,000 applicator units in Q1 2025, marking a 16.7% increase from Q4 2024 [1][3][8] - The company is advancing its late-stage pipeline, including the completion of an end-of-Phase 2 meeting with the FDA for VP-315, a candidate for basal cell carcinoma, and progressing towards a global Phase 3 program for common warts (VP-102/YCANTH) in collaboration with Torii Pharmaceutical [1][3][9] Financial Performance - For Q1 2025, Verrica recognized product revenue of $3.4 million, with costs of product revenue at $0.4 million, leading to a net loss of $9.7 million or $0.10 per share, compared to a net loss of $20.3 million or $0.44 per share in Q1 2024 [12][20] - Selling, general, and administrative expenses decreased to $8.8 million from $16.3 million year-over-year, primarily due to reduced commercial activity costs [12][20] - Research and development expenses were $2.3 million in Q1 2025, down from $4.9 million in the same period last year, reflecting a decrease in clinical trial expenses for VP-315 [12][20] Business Developments - The company appointed Noah L. Rosenberg, M.D., as Chief Medical Officer, bringing extensive experience in clinical development and product launches [6][7] - Dr. Gavin Corcoran was appointed to the Board of Directors, contributing significant R&D leadership experience [7] Product Insights - YCANTH (VP-102) is the first FDA-approved treatment for molluscum contagiosum, with a strong demand reflected in the dispensing of 10,102 applicator units in Q1 2025 [8][14] - The company plans to provide additional genomic and immune response data for VP-315 in mid-2025, following a positive end-of-Phase 2 meeting with the FDA [9]

FOR MORE INFORMATION, PLEASE CONTACT: Investors: John J Kirby Interim Chief Financial Officer jkirby@verrica.com Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518- 9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register. A live audio webcast of the call be accessed by visiting the investor relations sec ...

Company Overview - Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing medications for skin diseases that require medical interventions [3] - The company's product YCANTH (VP-102) is the first and only FDA-approved treatment for molluscum contagiosum, a viral skin infection affecting approximately 6 million people in the U.S., primarily children [3] - YCANTH (VP-102) is also being developed to address common warts, which represent a significant unmet need in medical dermatology [3] - Verrica has entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma [3] Upcoming Event - Jayson Rieger, PhD, MBA, President and CEO of Verrica, will present at the Citizens Life Sciences Conference in New York City on May 7, 2025, at 3:00 pm ET [1][2] - Participants can access a live webcast of the event through a link provided, with a replay available for 90 days post-event [2]

WEST CHESTER, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the 24 Annual Needham Virtual Healthcare Conference. Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com Verrica is ...

Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants John Fraunces - Director, Corporate Communications, LifeSci Advisors, IR Jayson Rieger - President and CEO John Kirby - Interim CFO Conference Call Participants Stacy Ku - TD Cowen Gregory Renza - RBC Capital Markets Kemp Dolliver - Brookline Capital Markets Operator Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals’ Fourth Quarter and Full Year 2024 Corpor ...